Clinical Trial Update: Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating GSK3359609 in combination with pembrolizumab and 5-FU-platinum chemotherapy for recurrent or metastatic head and neck squamous cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• 5-fluorouracil (5-FU) (5-fluorouracil)
• GSK3359609
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Head and Neck | Phase 3 | Status: TERMINATED | Results posted: 2022-05-25